Although the use of recombinant human erythropoietin in hemodialysis patients has resulted in improved hemoglobin levels and ameliorated the symptoms of anemia, significantly reducing the number of transfusions required, its use does not completely eliminate the need for blood transfusions in patients [21]–[23]. This evidence concerns the gene EPO and anemia.